Childhood vaccination associated adverse events by sex: A literature review

Travel Medicine and Infectious Disease

Volumn 12, Issue 5, 2014, Pages 459-480

  Weber, Sandra Köhli ^a   Schlagenhauf, Patricia ^b  

^a UNIVERSITY OF BASEL   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Adverse events; Childhood Sex; Hepatitis B vaccine (HBV); Human papilloma virus vaccine (HPV); Measles mumps rubella vaccine (MMR)

Indexed keywords

HEPATITIS B VACCINE; MEASLES MUMPS RUBELLA VACCINE; RECOMBINANT HEPATITIS B VACCINE; WART VIRUS VACCINE; VACCINE;

ADOLESCENT; ADVERSE DRUG REACTION; ALLERGIC URTICARIA; ANAPHYLACTOID PURPURA; APPENDICITIS; ARTHRALGIA; ARTHROPATHY; ARTICLE; ASTHMA; BRAIN DISEASE; BRONCHIOLITIS; CEREBROVASCULAR ACCIDENT; CHILD; COCHRANE LIBRARY; CONJUNCTIVITIS; DIABETES MELLITUS; DIARRHEA; DROWSINESS; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; EAR INFECTION; EMBASE; ENCEPHALITIS; EPILEPSY; FAINTNESS; FATIGUE; FEBRILE CONVULSION; GASTROENTERITIS; GASTROINTESTINAL SYMPTOM; GUILLAIN BARRE SYNDROME; HERPES SIMPLEX ENCEPHALITIS; HUMAN; IMMUNOGENICITY; INJECTION SITE DISCOLORATION; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; LOSS OF APPETITE; LYMPHADENOPATHY; MEDLINE; MENINGITIS; MYALGIA; NAUSEA; OTITIS MEDIA; PAROTITIS; PHARYNGITIS; PNEUMONIA; POSTMARKETING SURVEILLANCE; PRURITUS; PURPURA; RASH; RHINOPHARYNGITIS; SEROCONVERSION; SEX DIFFERENCE; SIDE EFFECT; STEVENS JOHNSON SYNDROME; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; URTICARIA; VACCINATION; VENOUS THROMBOEMBOLISM; VOMITING; ADULT; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; INFANT; MALE; PRESCHOOL CHILD; YOUNG ADULT;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; INFANT; MALE; VACCINES; YOUNG ADULT;

EID: 84908165011     PISSN: 14778939     EISSN: 18730442     Source Type: Journal    
DOI: 10.1016/j.tmaid.2014.01.008     Document Type: Article

References (60)

1. Centers for Disease Control and Prevention Ten great public health achievements - worldwide 2001-2010 http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6024a4.html [accessed 11.10.12]
2. Robert Koch Institut, Impfen. http://www.rki.de/DE/Content/Infekt/Impfen/impfen.html [accessed 11.10.12].
3. R.M. Jacobson Vaccinations: a public health triumph and a public relations tragedy. Mayo Clinic, USA Minn Med 95 8 2012 Aug 36 40
4. J.S. Gerber, and P.A. Offit Vaccines and autism: a tale of shifting hypotheses Clin Infect Dis 48 4 2009 456 461
5. A.J. Wakefield, S.H. Murch, A. Anthony, J. Linnell, D.M. Casson, and M. Malik Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children Lancet 35 1998 637 641
6. Global vaccine safety blueprint March 2012 WHO http://www.who.int/immunization-safety/activities/GVS-blueprint-project/en/index.html [accessed 11.10.12]
7. Bundesamt für Gesundheit, Masern. http://www.bag.admin.ch/themen/medizin/00682/00684/01087/index.html?lang=de [accessed 16.10.12].
8. World Health Organization (WHO). Guide to the WHO information sheets on observed rates of vaccine reactions: Immunization, Vaccines and Biologicals Department, Global Vaccine Safety; April 2012. http://www.who.int/vaccine-safety/initiative/tools/vaccinfosheets/en/ [accessed 18.11.2013]. http://www.who.int/vaccine-safety/initiative/tools/Guide-Vaccine-rates-information-sheet-.pdf [accessed 18.11.2013].
9. L. Wijnans, C. Lecomte, C. de Vries, D. Weibel, C. Sammon, and A. Hviid The incidence of narcolepsy in Europe: before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns Vaccine 31 8 2013 Feb 6 1246 1254
10. A. Amarasinghe, S. Black, J. Bonhoeffer, S.M. Carvalho, A. Dodoo, and J. Eskola Effective vaccine safety systems in all countries: a challenge for more equitable access to immunization Vaccine 31 Suppl. 2 2013 Apr 18 B108 B114
11. H.S. Izurieta, P. Zuber, J. Bonhoeffer, R.T. Chen, O. Sankohg, and K.F. Laserson Roadmap for the international collaborative epidemiologic monitoring of safety and effectiveness of new high priority vaccines Vaccine 31 35 2013 Aug 2 3623 3627
12. M.S. Gold, J. Buttery, and P. McIntyre Human papilloma virus vaccine safety in Australia: experience to date and issues for surveillance Sex Health 7 3 2010 Sep 320 324
13. I.F. Cook Sex differences in injection site reactions with human vaccines Hum Vaccin 5 7 2009 Jul 441 449
14. I.F. Cook Evidence versus expert opinion in vaccination practice Hum Vaccin 6 5 2010 May 374 376
15. R.M. Martins, G. Bensabath, L.C. Arraes, L. Oliveira Mde, J.C. Miguel, and G.G. Barbosa Multicenter study on the immunogenicity and safety of two recombinant vaccines against hepatitis B Mem Ist Oswaldo Cruz 99 8 2004 Dec 865 871
16. M.A. Fisher, S.A. Eklund, S.A. James, and X. Lin Adverse events associated with hepatitis B vaccine in U.S. children less than six years of age, 1993 and 1994 Ann Epidemiol 11 1 2001 Jan 13 21
17. M.T. Niu, D.M. Davis, and S. Ellenberg Recombinant hepatitis B vaccination of neonates and infants: emerging safety data from the Vaccine Adverse Event Reporting System Pediatr Infect Dis J 15 9 1996 Sept 771 776
18. A. Chowdhury, A. Santra, C.M. Habibullah, A.A. Khan, J. Karunakaramaiah, and T.S. Kishore Immune response to an indigenously developed r-hepatitis B vaccine in mixed population: study of an accelerated vaccination schedule World J Gastroenterol 11 7 2005 Feb 21 1037 1039
19. G. Leroux-Roels, B. Abraham, M. Fourneau, N. De Clercq, and A. Safary A comparison of two commercial recombinant vaccines for hepatitis B in adolescents Vaccine 19 7-8 2000 Nov 22 937 942
20. G. De Serres, B. Duval, N. Boulianne, M. Rochette, M. Dionne, and M.D. Fradet Importance of attributable risk in monitoring adverse events after immunization: hepatitis B vaccination in children Am J Public Health 91 2 2001 Feb 313 315
21. S. Dobson, D. Scheifele, and A. Bell Assessment of a universal, school-based hepatitis B vaccination program JAMA 274 15 1995 Oct 18 1209 1213
22. A. Patja, I. Davidkin, T. Kurki, M.J. Kallio, M. Valle, and H. Peltola Serious adverse events after measles-mumps-rubella vaccination during a fourteen-year prospective follow up Pediatr Infect Dis J 19 12 2000 Dec 1127 1134
23. J. Klinge, S. Lugauer, K. Korn, U. Heiniger, and K. Stehr Comparison of immunogenicity and reactogenicity of measles, mumps and rubella (MMR) vaccine in German children vaccinated at 9-11, 12-14 or 15-17 months of age Vaccine 18 27 2000 Jul 15 3134 3140
24. Charles W. LeBaron, Daoling Bi, Bradley J. Sullivan, Carol Beck, and Paul Gargiullo Evaluation of potentially common adverse events associated with the first and second dose of measles-mumps-rubella vaccine Pediatrics 118 4 2006 Oct 1422 1430
25. F.S. Lim, H.H. Han, and H.L. Bock Safety, reactogenicity and immunogenicity of the live attenuated combined measles, mumps, rubella vaccine containing the RIT 4385 mumps strain in healthy Singaporean children Ann Acad Med Singap 36 12 2007 Dec 969 973
26. A. Esteghamati, A. Keshtkar, R. Heshmat, M.M. Gouya, M. Salar Amoli, and S. Armin Adverse reactions following immunization with MMR vaccine in children at selected provinces of Iran Arch Iran Med 14 2 2011 Mar 91 95
27. H. Lee, H.W. Kim, H.K. Cho, E.A. Park, K.M. Choi, and K.H. Kim Reappraisal of MMR vaccines currently used in Korea Pediatr Int 53 3 2011 Jun 374 380
28. A. Mäkelä, J.P. Nuorti, and H. Peltola Neurologic disorders after measles-mumps-rubella vaccination Pediatrics 110 5 2002 Nov 957 963
29. A. Patja, S. Mäkinen-Kiljunen, I. Davidkin, M. Paunio, and H. Peltola Allergic reactions to measles-mumps-rubella vaccination Pediatrics 107 2 2001 Feb E27
30. B.A. Dos Santos, T.S. Ranieri, M. Bercini, M.T. Schermann, S. Famer, and R. Mohrdieck An evaluation of the adverse reaction potential of three measles-mumps-rubella combination vaccines Rev Panam Salud Publica 12 4 2002 Oct 240 246
31. M. Virtanen, H. Peltola, M. Paunio, and O.P. Heinonen Day-to-day reactogenicity and the healthy vaccine effect of measles-mumps-rubella vaccine Pediatrics 106 5 2000 Nov E62
32. R.L. Davis, E. Marcuse, S. Black, H. Shinefield, B. Givens, and J. Schwalbe MMR2 immunization at 4 to 5 years and 10 to 12 years of age: a comparison of adverse clinical events after immunization in the Vaccine Safety Datalink Project Pediatrics 100 5 1997 Nov 767 771
33. V. Demicheli, A. Rivetti, M.G. Debalini, and C. Di Pietrantonj Vaccines for measles, mumps and rubella in children Cochrane Database Syst Rev 2 2012 Feb 15 CD004407
34. C. Wood, C.L. von Baeyer, A. Bourrillon, V. Dejos-Conant, N. Clyti, and V. Abitbol Self-assessment of immediate post-vaccination pain after two different MMR vaccines administered as a second dose in 4- to 6-year-old children Vaccine 23 2 2004 Nov 25 127 131
35. T. Vesikari, E.L. Ala-Laurila, A. Heikkinen, A. Terho, E. D'Hondt, and F.E. André Clinical trial of a new trivalent measles-mumps-rubella vaccine in young children Am J Dis Child 138 9 1984 Sep 843 847
36. J.C. Watson, S.C. Hadler, C.A. Dykewicz, S. Reef, and L. Phillips Measles, mumps, and rubella-vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR Recomm Rep 47 RR-8 1998 May 22 1 57
37. V. Usonis, V. Bakasenas, K. Chitour, and R. Clemens Comparative study of reactogenicity and immunogenicity of new and established measles, mumps and rubella vaccines in healthy children Infection 26 4 1998 Jul-Aug 222 226
38. C.P. Farrington, E. Miller, and B. Taylor MMR and autism: further evidence against a causal association Vaccine 19 27 2001 Jun 14 3632 3635
39. J.M. Kelso, R.T. Jones, and J.W. Yunginger Anaphylaxis to measles, mumps, and rubella vaccine mediated by IgE to gelatin J Allergy Clin Immunol 91 1993 867 872
40. M. Sakaguchi, H. Ogura, and S. Inouye IgE antibody to gelatin in children with immediate-type reactions to measles and mumps vaccines J Allergy Clin Immunol 96 1995 563 565
41. M. Sakaguchi, T. Nakayama, and S. Inouye Food allergy to gelatin in children with systemic immediate-type reactions, including anaphylaxis, to vaccines J Allergy Clin Immunol 98 1996 1058 1061
42. M. Sakaguchi, T. Yoshida, T. Asahi, T. Aoki, Y. Miyatani, and S. Inouye Development of IgE antibody to gelatin in children with systemic immediate-type reactions to vaccines J Allergy Clin Immunol 99 1997 720 721
43. K. Taniguchi, T. Fujisawa, T. Ihara, and H. Kamiya Gelatin-induced T-cell activation in children with nonanaphylactic-type reactions to vaccines containing gelatin J Allergy Clin Immunol 102 1998 1028 1032
44. J.M. Kelso The gelatin story J Allergy Clin Immunol 103 1999 200 202
45. K.P. Garnock-Jones, and A.R. Giuliano Quadrivalent human papilloma virus (HPV) types 6, 11, 16, 18 Vaccine: for the prevention of genital warts in males Drugs 71 5 2011 Mar 26 591 602
46. S.L. Block, T. Nolan, C. Sattler, E. Barr, K.E. Giacoletti, and C.D. Marchant Comparison of immunogenicity and reactogenicity of a prophylactic quadrivalent human papilloma virus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women Pediatrics 118 5 2006 Nov 2135 2145
47. K.S. Reisinger, S.L. Block, E. Lazcano-Ponce, R. Samakoses, M.T. Esser, and J. Erick Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents Pediatr Infect Dis J 26 3 2007 Mar 201 209
48. T.F. Schwarz, L.M. Huang, D.M. Medina, A. Valencia, T.Y. Lin, and U. Behre Four-year follow-up of the immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine when administered to adolescent girls aged 10-14years J Adolesc Health 50 2 2012 Feb 187 194
49. S. Khatun, S.M. Akram Hussain, S. Chowdhury, J. Ferdous, F. Hossain, and S.R. Begum Safety and immunogenicity profile of human papillomavirus-16/18 AS04 adjuvanted cervical cancer vaccine: a randomized controlled trial in healthy adolescent girls in Bangladesh Jpn J Clin Oncol 42 1 2012 Jan 36 41
50. R. Gasparini, P. Bonanni, M. Levi, A. Bechini, S. Boccalini, and E. Tiscione Safety and tolerability of bivalent HPV vaccine: an Italian post-licensure study Hum Vaccin 7 Suppl. 2011 Jan-Feb 136 146
51. J. Gee, A. Naleway, I. Shui, J. Baggs, R. Yin, and R. Li Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink Vaccine 29 46 2011 Oct 26 8279 8284
52. Y. Singh, A. Shah, M. Singh, S. Verma, B.M. Shrestha, and P. Vaidya Human papilloma virus vaccination in Nepal: an initial experience Asian Pac J Cancer Prev 11 3 2010 615 617
53. C. Pedersen, T. Petaja, G. Strauss, H.C. Rumke, A. Poder, and J.H. Richardus Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant J Adolesc Health 40 6 2007 Jun 564 571
54. T.M. van Klooster, J.M. Kemmeren, N.A. van der Maas, and H.E. de Melker Reported adverse events in girls aged 13-16 years after vaccination with the human papillomavirus (HPV)-16/18 vaccine in the Netherlands Vaccine 29 28 2011 Jun 20 4601 4607
55. A.L. Naleway, R. Gold, L. Drew, K. Riedlinger, M.L. Henninger, and J. Gee Reported adverse events in young women following quadrivalent human papillomavirus vaccination J Womens Health (Larchmt) 21 4 2012 Apr 425 432
56. H.B. Jenson, and R.S. Baltimore Human papillomavirus vaccine: now for boys too? Curr Opin Pediatr 23 1 2011 Feb 78 84
57. R. Li, Y. Li, D. Radley, Y. Liu, T. Huang, and H.L. Sings Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: a randomized, double-blind, placebo-controlled trial in Chinese males and females Vaccine 30 28 2012 Jun 13 4284 4291
58. K.M. Neuzil, G. Canh do, V.D. Thiem, A. Janmohamed, V.M. Huong, and Y. Tang Immunogenicity and reactogenicity of alternative schedules of HPV vaccine in Vietnam: a cluster randomized noninferiority trial JAMA 305 14 2011 Apr 13 1424 1431
59. B.A. Slade, L. Leidel, C. Vellozzi, E.J. Woo, W. Hua, and A. Sutherland Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine JAMA 302 7 2009 Aug 19 750 757
60. T.C. Pomfret, J.M. Gagnon Jr., and A.T. Gilchrist Quadrivalent human papillomavirus (HPV) vaccine: a review of safety, efficacy, and pharmacoeconomics J Clin Pharm Ther 36 1 2011 Feb 1 9